NMN Improves PCOS Features in Rats by Boosting Ovarian Cell Metabolism
NMN improved hormone and metabolic problems in rats with PCOS, revealing a possible treatment target—not evidence of benefits in women.
Summary
A study in rats and laboratory-grown cells suggests that NMN, a supplement marketed for longevity, could influence the biology of polycystic ovary syndrome, or PCOS. Researchers induced PCOS-like problems in female rats, then gave them NMN or a control treatment for 30 days. NMN improved insulin resistance, excess male-type hormone levels, reproductive cycle irregularities, and abnormal ovarian appearance. It also increased a molecule involved in energy production and helped ovarian support cells break down glucose. Cell experiments linked these effects to an enzyme that changes how another energy-related protein functions. These findings identify a possible treatment pathway, but they do not show that NMN treats PCOS in women. The high rat dose is not a human dosing recommendation. This summary is based on the abstract only.
Detailed Summary
Polycystic ovary syndrome, or PCOS, can disrupt menstrual cycles and hormone balance while contributing to insulin resistance. Researchers tested whether nicotinamide mononucleotide, known as NMN, could improve these problems by restoring energy production in ovarian cells. The findings connect a popular longevity supplement with reproductive and metabolic biology, but remain entirely preclinical.
The team created a PCOS model in female rats using letrozole and a diet high in fat for 30 days. Afterward, rats were randomly assigned to receive either NMN at 500 milligrams per kilogram daily or a control treatment for another 30 days. Laboratory experiments also used a human ovarian cell line exposed to testosterone.
NMN improved insulin resistance, excess androgen levels, disrupted reproductive cycles, and abnormal ovarian appearance in the rats. It also increased ovarian NAD+, a molecule involved in cellular energy reactions, and enhanced glucose breakdown. These results suggest benefits across several PCOS features, rather than an isolated change in a single laboratory marker.
Mechanistic experiments implicated SIRT2, an enzyme that removes acetyl groups from proteins. NMN promoted removal of one such group at position 119 on LDHA, an enzyme involved in glucose metabolism. This change increased enzyme activity and energy metabolism in ovarian support cells, while promoting cell growth and reducing programmed cell death.
These findings identify a possible treatment target, not an established therapy for women with PCOS. The abstract provides no sample sizes, numerical effect estimates, detailed safety results, or evidence of improved pregnancy or live birth outcomes. The rat dose should not be treated as a human supplement recommendation. This summary is based on the abstract only; full methods and results were unavailable for assessment. Human trials are needed to establish whether NMN offers meaningful benefits, determine appropriate dosing, and evaluate safety before these findings can reliably guide routine clinical care decisions.
Key Findings
- NMN improved insulin resistance, excess androgen levels, reproductive cycle irregularities, and ovarian morphology in a rat model of PCOS.
- Rats received NMN at 500 mg/kg daily for 30 days; this is not an established dose for women.
- NMN increased ovarian NAD+ and glucose breakdown, linking its effects to cellular energy metabolism.
- Cell experiments implicated SIRT2-mediated removal of an acetyl group from LDHA at lysine 119.
- The study provides no clinical evidence that NMN improves PCOS symptoms, fertility, or safety outcomes in women.
Methodology
Researchers induced PCOS in female rats with letrozole at 1 mg/kg daily plus a high-fat diet for 30 days, then randomized affected rats to vehicle or NMN for another 30 days. Mechanistic experiments used testosterone-treated human granulosa-like KGN cells, protein interaction assays, and site-directed mutagenesis to investigate SIRT2 and LDHA.
Study Limitations
This summary is based on the abstract only, which does not report sample sizes, numerical effect estimates, or detailed safety findings. An induced rat model and a human cell line cannot establish clinical benefits in women, and the study does not demonstrate improved pregnancy or live birth outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: